European Archives - Page 538 of 1232 - European Medical Journal

EMJ Hematology 11 [Supplement 1] 2023

Gene therapy for haemophilia A and B was discussed during several sessions at the 64th American Society of Hematology (ASH) Annual Meeting, held 10th–13th December 2022.

Antimicrobial Resistance in Urinary Tract Infections: Is There an Issue and Does It Matter?

Antimicrobial resistance (AMR) has increased substantially among community-acquired uropathogens that cause urinary tract infections (UTI), limiting the availability of effective oral antibiotic treatments. This review includes coverage of an expert-led Learning Lounge, symposium session, and several poster presentations, that took place between 20th–22nd October 2022 as part of IDWeek2022 in Washington, D.C., USA.

EMJ Microbiology and Infectious Diseases 4 [Supplement 2] 2023

Antimicrobial resistance (AMR) has increased substantially among community-acquired uropathogens that cause urinary tract infections (UTI), limiting the availability of effective oral antibiotic treatments. This review includes coverage of an expert-led Learning Lounge, symposium session, and several poster presentations, that took place between 20th–22nd October 2022 as part of IDWeek2022 in Washington, D.C., USA.

Realising the Promise of Gene Therapy for Haemophilia: Current Status and Future Innovations

Gene therapy for haemophilia A and B was discussed during several sessions at the 64th American Society of Hematology (ASH) Annual Meeting, held 10th–13th December 2022.

Conquering generational differences in HCP marketing

What are the generation differences in how HCPs want to talk to pharma? Three generations of doctors share their thoughts.

Meet GOLD's new catalyst – AZ’s Mina Makar

Helena and Isabel share exclusive clips from the conversation with GOLD’s latest Catalyst interviewee: AstraZeneca’s Mina Makar.

A Review of the Latest Advancements in Ovarian Cancer Care Featured at ESMO 2022

Ovarian cancer is the seventh most commonly diagnosed cancer among females and the most lethal gynaecologic malignancy globally because of its vague presentation, insidious nature, recurrence, and drug resistance.

EMJ Oncology 11 [Supplement 1] 2023

This article reviews key updates on ovarian cancer research that were presented at the European Society for Medical Oncology (ESMO) Congress 2022.

Mina Makar on tackling unmet patient needs

AstraZeneca’s Mina Makar talks about solving unmet needs and how to champion the patient perspective.

The Twitter scandal that scared off pharma marketers

Many top pharma companies have cut their Twitter ad spend after the Eli Lilly scandal, but should they take a risk and return?